Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

701. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. Full Text available with Trip Pro

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. In cross-sectional studies, elevated plasma homocysteine levels have been associated with poor cognition and dementia. Studies of newly diagnosed dementia are required in order to establish whether the elevated homocysteine levels precede the onset of dementia or result from dementia-related nutritional and vitamin deficiencies.A total of 1092 subjects without dementia (667 women and 425 men; mean age, 76 years) from (...) the Framingham Study constituted our study sample. We examined the relation of the plasma total homocysteine level measured at base line and that measured eight years earlier to the risk of newly diagnosed dementia on follow-up. We used multivariable proportional-hazards regression to adjust for age, sex, apolipoprotein E genotype, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B12 and B6.Over a median follow-up period of eight years, dementia developed in 111

2002 NEJM

702. Alcohol consumption and risk of dementia: the Rotterdam Study. (Abstract)

Alcohol consumption and risk of dementia: the Rotterdam Study. Light-to-moderate alcohol consumption reduces the risk of coronary heart disease and stroke. Because vascular disease is associated with cognitive impairment and dementia, we hypothesised that alcohol consumption might also affect the risk of dementia.We examined the relation between alcohol consumption and risk of dementia in individuals taking part in the Rotterdam Study--a prospective population-based study of 7983 individuals (...) aged 55 years and older. We studied all participants who did not have dementia at baseline (1990-93) and who had complete data on alcohol consumption (n=5395). Through follow-up examinations in 1993-94 and 1997-99 and an extensive monitoring system, we obtained nearly complete follow-up (99.7%) until the end of 1999. We used proportional hazards regression analysis, adjusted for age, sex, systolic blood pressure, education, smoking, and body-mass index, to compare the risk of developing dementia

2002 Lancet

703. Risk of dementia among white and African American relatives of patients with Alzheimer disease. (Abstract)

Risk of dementia among white and African American relatives of patients with Alzheimer disease. Evidence exists that the incidence of Alzheimer disease (AD), as well as risk attributable to specific genetic factors such as apolipoprotein E (APOE) genotype, may vary considerably among ethnic groups. Family studies of probands with AD offer an opportunity to evaluate lifetime risk of dementia among relatives of these probands.To compare lifetime dementia risk estimates among relatives of white (...) and African American probands with probable or definite AD.Risk analysis using data collected by questionnaire and supplemental records between May 1991 and March 2001 at 17 medical centers contributing to the Multi-Institutional Research in Alzheimer's Genetic Epidemiology Study.A total of 17 639 first-degree biological relatives and 2474 spouses of 2339 white AD probands, and 2281 first-degree biological relatives and 257 spouses of 255 African American AD probands.Cumulative risk of dementia by age 85

2002 JAMA

704. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. (Abstract)

Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. There is increasing interest in preventing cognitive impairment and dementia in later life. Epidemiological evidence shows a relationship between cognitive impairment and Type II diabetes. This association is stronger in patients who have been diagnosed for longer periods of time and in those who are on insulin therapy. There is little information on the short- and long-term influence

2002 Cochrane

705. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Fajemisin B Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fajemisin B. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 9 Authors' objectives This study aims to assess the effects of acetylcholinesterase inhibitors (donepezil, rivastigmine, tacrine, galantamine) on functional outcomes in people with non-Alzheimer's dementia. Authors' conclusions We found

2002 Health Technology Assessment (HTA) Database.

706. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. (Abstract)

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of dementia in many patients with Alzheimer's disease. Galantamine amplifies the acetylcholine response by inhibiting acetylcholinesterase and modulating nicotinic receptors. It has shown broad, sustained benefits in patients with Alzheimer's disease (...) . We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease.Eligible patients were randomly assigned galantamine 24 mg/day (n=396) or placebo (n=196) in a multicentre, double-blind, 6-month trial. Primary endpoints were cognition (Alzheimer's disease assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input

2002 Lancet Controlled trial quality: predicted high

707. Interventions for family members caring for an elder with dementia

Interventions for family members caring for an elder with dementia Interventions for family members caring for an elder with dementia Interventions for family members caring for an elder with dementia Acton G J, Winter M A Authors' objectives To investigate what family caregiver interventions have been tested, and to identify what features are important for nurses to consider. The review aimed to identify important issues for research and researchers. Searching MEDLINE, CINAHL, Social Science (...) . Participants included in the review Studies of care givers of adults with dementia or with cognitive impairment were reviewed. It was unclear from the paper whether or not studies of those being cared for were also included. Outcomes assessed in the review The outcomes reviewed were dysphoric variables, positive psychosocial variables, perceived physical health and the rate of institutionalisation. How were decisions on the relevance of primary studies made? The authors do not state how the papers were

2002 DARE.

708. Snoezelen: an overview of research with people with developmental disabilities and dementia

Snoezelen: an overview of research with people with developmental disabilities and dementia Snoezelen: an overview of research with people with developmental disabilities and dementia Snoezelen: an overview of research with people with developmental disabilities and dementia Lancioni G E, Cuvo A J, O'Reilly M F Authors' objectives To present an overview of the research studies on snoezelen with people with developmental disabilities and dementia, and to discuss the findings in relation (...) , playroom sessions, free-activity and activity sessions. Participants included in the review Studies of people with developmental disabilities or dementia were eligible for inclusion in the review. The studies included: people with profound intellectual or multiple disabilities, with or without challenging behaviour; children with moderate or severe mental retardation and stereotyped behaviour; and older adults with dementia (most aged over 65 years). Outcomes assessed in the review All outcomes appear

2002 DARE.

709. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience

Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience Kindermann S S, Dolder C R, Bailey A, Katz I R, Jeste D V Authors' objectives To assess the efficacy of drugs used for treating psychosis, aggression (...) and agitation in elderly patients with dementia. Searching MEDLINE and the Science Citation Index were searched from 1960 to 2000 for publications in the English language. Recent reviews and bibliographies of identified studies were also examined. The keywords were provided. Study selection Study designs of evaluations included in the review Studies with fewer than ten patients were excluded. Studies in the review included randomised controlled trials (RCTs) both open and double-blind, non-randomised

2002 DARE.

710. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits

Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits Silverman D H S, Gambhir S S, Huang H W C, Schwimmer J, Kim S, Small G W, Chodosh (...) of Alzheimer's disease (AD), the most common cause of dementia in the geriatric population. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population The study population comprised geriatric patients with cognitive impairment, which could potentially represent the early manifestations of AD. Setting The setting of the study was not clearly reported but appears to have been secondary care. The economic study was carried out in the USA. Dates to which data relate Data

2002 NHS Economic Evaluation Database.

711. Care management, dementia care and specialist mental health services: an evaluation Full Text available with Trip Pro

Care management, dementia care and specialist mental health services: an evaluation Care management, dementia care and specialist mental health services: an evaluation Care management, dementia care and specialist mental health services: an evaluation Challis D, von Abendorff R, Brown P, Chesterman J, Hughes J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The provision of a dedicated care manager within a community mental health team for the elderly with dementia. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised elderly persons in the UK who were living in the community, mostly alone, with cognitive impairment. Setting The setting

2002 NHS Economic Evaluation Database.

712. Touch massage for dementia

Touch massage for dementia Touch massage for dementia We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Touch massage for dementia Share: Reading time approx. 5 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert Version: 1 Technology and target group Touch massage can be used (...) as a general term to cover, eg, tactile stimulation, peripheral tactile nerve stimulation, tactile massage, aromatherapy massage, hand massage, expressive physical touch, and effleurage. Touch massage is given to patients, eg, with dementia, as a complement to other treatment and nursing care, as a part of daily care activities. The aims of treatment are to give patients a greater sense of well-being, reduce stress, and relieve pain, thereby decreasing anxiety and aggressive behaviors in the patient. Touch

2002 Swedish Council on Technology Assessement

713. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. (Abstract)

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined.To assess the sensitivity and specificity with which cerebral metabolic patterns at a single point in time forecast subsequent documentation of progressive dementia.Positron emission (...) tomography (PET) studies of [(18)F]fluorodeoxyglucose in 146 patients undergoing evaluation for dementia with at least 2 years' follow-up for disease progression at the University of California, Los Angeles, from 1991 to 2000, and PET studies in 138 patients undergoing evaluation for dementia at an international consortium of facilities, with histopathological diagnoses an average of 2.9 years later, conducted from 1984 to 2000.Regional distribution of [(18)F]fluorodeoxyglucose in each patient

2001 JAMA

714. In-vivo measurement of activated microglia in dementia. (Abstract)

In-vivo measurement of activated microglia in dementia. Activated microglia have a key role in the brain's immune response to neuronal degeneration. The transition of microglia from the normal resting state to the activated state is associated with an increased expression of receptors known as peripheral benzodiazepine binding sites, which are abundant on cells of mononuclear phagocyte lineage. We used brain imaging to study expression of these sites in healthy individuals and patients (...) -dependent increase was found. By contrast, patients with Alzheimer's disease showed significantly increased regional [11C](R)-PK11195 binding in the entorhinal, temporoparietal, and cingulate cortex.In-vivo detection of increased [11C](R)-PK11195 binding in Alzheimer-type dementia, including mild and early forms, suggests that microglial activation is an early event in the pathogenesis of the disease.

2001 Lancet

715. Haloperidol for agitation in dementia. (Abstract)

Haloperidol for agitation in dementia. Agitation includes wandering, crying out, abusive vocalization, and assaultive behavior and occurs in up to 70% of patients with dementia. Although the neuroleptic haloperidol has been used for decades to control disruptive behavior in psychotic and demented patients, the effectiveness of this drug for agitated dementia remains in question. The first meta-analysis on the effectiveness of haloperidol for agitated dementia, published in 1990, was limited (...) in scope and was unable to provide clear guidelines for the use of haloperidol for demented patients who are agitated. Meta-analyses in 1998 and 2000 examined haloperidol compared with other neuroleptics as well as with placebo and omitted a number of databases, including non-English language publications. To determine the effect of haloperidol, compared with placebo, in the control of agitated dementia and to make recommendations for future research in this area a more widely based, yet more highly

2001 Cochrane

716. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Full Text available with Trip Pro

Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Nicergoline is an ergot derivative currently in use in over fifty countries for more than three decades, for the treatment of cognitive, affective, and behavioral disorders of older people. It was initially considered as a vasoactive drug and mainly prescribed for cerebrovascular disorders. Recent findings suggest other actions which has provided a rationale for the use of nicergoline for the treatment (...) of various forms of dementia, including Alzheimer's Disease.To determine whether there is evidence of efficacy of nicergoline in the treatment of dementia and other age-associated forms of cognitive decline,and to assess the safety and tolerability of the drug.1. Electronic databases search. The Cochrane Controlled Trials Register (which contains citations from the MEDLINE, EMBASE, Psych LIT, and hand searches of geriatric, dementia, psychogeriatric journals, and conference abstracts) was searched using

2001 Cochrane

717. Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia

Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia Matchar DB, Kulasingam SL, McCrory DC, Patwardhan MB, Rutschmann OT, Samsa GP (...) , Schmechel DE Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Matchar DB, Kulasingam SL, McCrory DC, Patwardhan MB, Rutschmann OT, Samsa GP, Schmechel DE. Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia. Rockville: Agency for Healthcare Research and Quality

2001 Health Technology Assessment (HTA) Database.

718. Drugs for non-Alzheimer's dementia - horizon scanning review

Drugs for non-Alzheimer's dementia - horizon scanning review Drugs for non-Alzheimer's dementia - horizon scanning review Drugs for non-Alzheimer's dementia - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Drugs for non-Alzheimer's dementia - horizon scanning review. Birmingham: National Horizon (...) Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on acetylcholinesterase inhibitors for non-Alzheimer's dementia (non-AD). Authors' conclusions - Clinical impact: The extension of clinical indications to non-AD dementia may have a significant clinical impact on individuals with these types of dementia. - Service impact: There is often difficulty in distinguishing the exact cause of dementia. If clinical trials are positive

2001 Health Technology Assessment (HTA) Database.

719. Memantine for Alzheimer's disease and vascular dementia - horizon scanning review

Memantine for Alzheimer's disease and vascular dementia - horizon scanning review Memantine for Alzheimer's disease and vascular dementia - horizon scanning review Memantine for Alzheimer's disease and vascular dementia - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Memantine for Alzheimer's disease (...) and vascular dementia - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on memantine for Alzheimer's disease and vascular dementia. Authors' conclusions - Clinical impact: Memantine is the first treatment being developed for patients suffering from moderate to severe Alzheimer's disease and for patients suffering from vascular dementia. This is a growing patient group

2001 Health Technology Assessment (HTA) Database.

720. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. (Abstract)

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Results of epidemiological studies, neuropathological observations, and in-vitro experiments all suggest that inflammatory mechanisms contribute to the destructive lesions in Alzheimer's disease. We aimed to establish the effect of the anti-inflammatory drug hydroxychloroquine on the progression of dementia.We did a double-blind, parallel-group (...) , multicentre trial in which we randomly assigned 168 patients with early Alzheimer's disease to hydroxychloroquine (200 or 400 mg dependent on bodyweight), or placebo for 18 months. Outcome measures were related to activities of daily living, cognitive function, and behavioural abnormalities. Analysis was by intention to treat.At 18 months, mean scores for the interview for deterioration in daily life in dementia in patients on hydroxychloroquine (22.6 [SD 11.4]) did not differ from those for patients

2001 Lancet Controlled trial quality: predicted high